關於 atezolizumab ，我們在網路上蒐集到這些相關的討論、資訊與評價

#11. Tecentriq | European Medicines Agency - europa.eu

atezolizumab. Therapeutic area (MeSH). Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Urologic Neoplasms; Breast Neoplasms ...

#12. Atezolizumab for First-Line Treatment of PD-L1 ... - PubMed

Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with ...

#13. Atezolizumab (Tecentriq) - Drug Information | Chemocare

Atezolizumab is the generic name for the trade drug name Tecentriq™. In some cases, health care professionals may use the generic name atezolizumab when ...

#14. Atezolizumab Injection: MedlinePlus Drug Information

Atezolizumab injection is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells.

#15. A Study of Atezolizumab in Combination With Bevacizumab ...

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular ...

#16. Tecentriq Prescribing Information - Genentech

TECENTRIQ safely and effectively. See full prescribing information for. TECENTRIQ. TECENTRIQ® (atezolizumab) injection, for intravenous use.

#17. Tecentriq 1200 mg concentrate for solution for infusion - eMC

*Atezolizumab is an Fc-engineered, humanised IgG1 anti-programmed death-ligand 1 (PD-L1) monoclonal antibody produced in Chinese hamster ovary cells by ...

#18. Definition of atezolizumab - NCI Drug Dictionary

A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune ...

#19. Atezolizumab plus Bevacizumab in Unresectable ...

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes ...

#20. Tecentriq (atezolizumab) dosing, indications, interactions ...

Adjuvant non-small cell lung cancer (NSCLC) · Indicated as adjuvant treatment following resection and platinum-based chemotherapy for adults with stage II to ...

#21. Atezolizumab (Intravenous Route) - Mayo Clinic

Atezolizumab injection is used to treat urothelial carcinoma (a type of bladder cancer) that has spread throughout the body (metastatic) or cannot be ...

#22. TECENTRIQ® (atezolizumab) HCP | Efficacy, Safety, PI & MOA

TECENTRIQ is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who: ... This indication is approved under ...

#23. Atezolizumab in Metastatic Triple-Negative Breast Cancer ...

These trials tested the benefit of adding atezolizumab to taxane in first-line treatment of mTNBC. IMpassion130 demonstrated a progression-free ...

#24. Cancer Immunotherapy Treatment for NSCLC, ES-SCLC ...

Learn about TECENTRIQ® (atezolizumab), a cancer Immunotherapy treatment for Non-Small Cell Lung Cancer after surgery and chemo, Metastatic Non-Small Cell ...

#25. Atezolizumab Appears Effective for Patients with NSCLC with ...

The findings from this global, open-label, randomized trial supported the FDA approval of atezolizumab for patients with non-small cell lung ...

#26. IMpower010: Primary results of a phase III global study of ...

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected ...

#27. FDA Approves Adjuvant Atezolizumab for PD-L1+ Non–Small ...

The FDA has granted approval to atezolizumab (Tecentriq) as adjuvant treatment following surgery and platinum-based chemotherapy for people ...

#28. Atezolizumab - an overview | ScienceDirect Topics

Atezolizumab is an antibody that binds to PD-L1, thereby blocking the PD-L1/PD-1 signaling pathway. When administered to a cancer patient, atezolizumab removes ...

#29. Next generation of anti-PD-L1 Atezolizumab with enhanced ...

FDA-approved anti-PD-L1 antibody drug Atezolizumab is a human IgG1 without glycosylation by an N297A mutation. Aglycosylation of IgG1 has ...

#30. ATEZOLIZUMAB | Drug | BNF content published by NICE

Atezolizumab is a monoclonal antibody, which binds to the programmed death-ligand 1 (PD-L1), thereby reactivating the immune response to tumour cells.

#31. Atezolizumab Improves DFS Over BSC in PD-L1+ Resectable ...

The PD-L1 inhibitor atezolizumab was found to improve disease-free survival over best supportive care when used as an adjuvant treatment in ...

#32. KEGG DRUG: Atezolizumab - genome.jp

Atezolizumab (genetical recombination) (JAN); Tecentriq (TN). Product. TECENTRIQ (Genentech). Formula. C6446H9902N1706O1998S42. Exact mass. 144521.3941.

#33. 臺大鄭安理團隊Atezolizumab + Bevacizumab組合治療晚期 ...

臺大鄭安理團隊Atezolizumab + Bevacizumab組合治療晚期肝癌OS、PFS優於一線用藥sorafenib三期臨床結果登《NEJM》. 2020.05.18環球生技雜誌/記者 ...

#34. Carboplatin, paclitaxel, atezolizumab, and bevacizumab [1]

There is no standard premedication for atezolizumab, bevacizumab, or carboplatin. Refer to UpToDate topic on "Infusion reactions to systemic chemotherapy".

#35. Atezolizumab (anti-PD-L1) | PD-1/PD-L1 inhibitor - Selleck ...

By blocking the PD-L1/PD-1 immune checkpoint, atezolizumab reduces immunosuppressive signals found within the tumor microenvironement and consequently increases ...

#36. Atezolizumab Reduces Risk of Disease Progression in ...

Atezolizumab given after chemotherapy to patients with resected stage II to IIIA non–small cell lung cancer (NSCLC) significantly improved ...

#37. FDA Approves Atezolizumab as Adjuvant Treatment for Non ...

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment ...

#38. Atezolizumab Uses, Side Effects & Warnings - Drugs.com

Atezolizumab is used to treat certain cancers of the breast, skin, lung, liver, or bladder and urinary tract. Atezolizumab is used when the ...

#39. Atezolizumab (Tecentriq®) | OncoLink

Atezolizumab works as a form of immunotherapy and blocks the activity of programmed death ligand 1 (PDL-1), a molecule found on T cells that suppresses immune ...

#40. Atezolizumab ELISA Assay Kit - Eagle Biosciences

The Atezolizumab ELISA Assay Kit is for the determination of Atezolizumab in serum, plasma, and cell culture supernatants.

#41. IMpower150 Final Overall Survival Analyses for Atezolizumab ...

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC · Mark A ...

#42. Comparative Efficacy of Atezolizumab plus Bevacizumab and ...

Keywords: Hepatocellular carcinomaCancer immunotherapyAtezolizumabMeta- ... HCC and no prior systemic treatment, including atezolizumab plus bevacizumab, ...

#43. atezolizumab | Cancer Care Ontario

For treating a certain type of bladder cancer called urothelial carcinoma or a type of lung cancer called Non-Small-Cell Lung Cancer (NSCLC). · Atezolizumab is ...

#44. Atezolizumab | Memorial Sloan Kettering Cancer Center

Atezolizumab. Adult Medication. Share. Print. This information from Lexicomp ® explains what you need to know about this medication, ...

#45. Atezolizumab (Tecentriq ) and other immune-stimulatory anti ...

Atezolizumab (Tecentriq▽) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs).

#46. atezolizumab (Tecentriq) - Scottish Medicines Consortium

Indication under review: Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable ...

#47. Atezolizumab plus bevacizumab combination enables an ...

We reported a patient with unresectable hepatocellular carcinoma (HCC) who initially received 15 cycles of atezolizumab plus bevacizumab ...

#48. Atezolizumab and bevacizumab for hepatocellular carcinoma

#Immunotherapy combinations such as #atezolizumab plus #bevacizumab: future standard treatment for patients with unresectable #hepatocellular ...

#49. Atezolizumab - Macmillan Cancer Support

Atezolizumab is used to treat some types of advanced (metastatic) cancer including: · Bladder, ureter and renal pelvis cancers are known as urothelial cancers.

#50. Atezolizumab Versus Chemotherapy in Patients with Platinum ...

Atezolizumab is an anti–PD-L1 immune checkpoint inhibitor recommended for the treatment of locally advanced or metastatic urothelial ...

#51. Atezolizumab (Tecentriq) + Vemurafenib (Zelboraf ...

Atezolizumab is a PD-L1 drug that promotes the tumor-killing effects of T-cells (white blood cells that help your body fight disease). Vemurafenib is a BRAF ( ...

#52. FDA Approves Atezolizumab as Adjuvant Treatment in Certain ...

Atezolizumab is a monoclonal antibody designed to bind with PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its ...

#53. 藥品資料

主成份及含量：, Atezolizumab 1200 mg/vial. 適應症(藥袋列印)： ... 免疫檢查點PD-1、PD-L1抑制劑(如atezolizumab；nivolumab；pembrolizumab；avelumab ...

#54. 3408-NSCLC locally advanced or metastatic atezolizumab

BACKGROUND: Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 ...

#55. Atezolizumab in patients with renal insufficiency and mixed ...

Background Atezolizumab is a treatment for locally advanced/metastatic urothelial carcinoma (mUC). However, its use in patients with renal insufficiency or ...

#56. FDA Approves Tecentriq (Atezolizumab) for Small Cell Lung ...

The US Food and Drug Administration (FDA) has approved the immunotherapy drug Tecentriq (atezolizumab) for the treatment of small cell lung ...

#57. Atezolizumab Combo Approved for PD-L1–positive TNBC

The first immune checkpoint inhibitor regimen for breast cancer earned FDA approval on March 8, when the FDA greenlighted atezolizumab ...

#58. 商品名：Tecentriq 學名：Atezolizumab 使用方式：1200mg/vial

學名：Atezolizumab. 使用方式：1200mg/vial、Q3W、IVD 一小時(初次注射後無不良反應之後可縮短為30 分鐘). 台灣衛福部適應症：. 1.1 局部晚期或轉移性泌尿道上皮癌.

#59. DRUG NAME: Atezolizumab - BC Cancer

Atezolizumab is a humanized IgG1 monoclonal antibody immune checkpoint inhibitor that binds to programmed death-ligand 1 (PD-L1) and blocks ...

#60. Genentech Pulls Atezolizumab's Breast Cancer Approval

The FDA granted accelerated approval of atezolizumab and nab-paclitaxel on the basis of the IMpassion130 trial, which showed significant ...

#61. 財團法人醫藥品查驗中心醫療科技評估報告補充資料

整體來說，加拿大CADTH、澳洲PBAC 及英國NICE 大多認為atezolizumab 與 carboplatin 及etoposide 合併使用作為擴散期小細胞肺癌成年病人之第一線治療所帶. 來的整體存活期( ...

#62. Atezolizumab | Cancer information | Cancer Research UK

Atezolizumab is a type of immunotherapy drug. You might have it as a treatment for cancer of the bladder or urinary system.

#63. Atezolizumab for the First-Line Treatment of Non-small Cell ...

Atezolizumab is a PDL-1 inhibitor that was designed to restore anti-tumor action by preventing the immunosuppression caused by the B7H-1 and the ...

#64. Atezolizumab: Uses, Interactions, Mechanism of Action

Phase Status Purpose Count 4 Active Not Recruiting Treatment 1 4 Active Not Recruiting Treatment 1 4 Recruiting Diagnostic 1

#65. 癌自禦Atezolizumab Tecentriq - 大腸直腸癌即時照護網

癌自禦Atezolizumab Tecentriq 也是屬於免疫治療的藥物。 其作用機轉是anti PD-L1 的抗體。 ... 1.局部晚期或轉移性泌尿道上皮癌: 適用於治療接受含鉑化學治療後疾病惡化或 ...

#66. [期刊閱讀]Atezolizumab搭配Bevacizumab成為肝癌治療新選擇？

Atezolizumab 搭配Bevacizumab成為肝癌治療新選擇？ 背景知識| NEJM在2020年5月14日刊登了一篇由台大醫院附設癌醫中心院長鄭安理理等人發表的研究， ...

#67. Mechanisms of action of atezolizumab and bevacizumab. (A ...

Download scientific diagram | Mechanisms of action of atezolizumab and bevacizumab. (A) Atezolizumab is a monoclonal antibody against PD-L1.

#68. Atezolizumab (TECENTRIQ®) 中文名:癌自禦1200mg/20mL/via

Atezolizumab 是免疫檢查點抑制劑，屬於人類IgG1 單株抗體。此種藥品會與腫. 瘤上的PD-L1 蛋白結合，使PD-1 和B7-1 不能與腫瘤上PD-L1 結合。 PD-L1 是.

#69. Atezolizumab-藥品(物)/適應症/副作用查詢 - KingNet國家網路醫藥

(1)適用於治療接受含鉑化學治療後疾病惡化或不適合含cisplatin療法之局部晚期或轉移性泌尿道上皮癌患者。(2)適用於治療接受含鉑化學治療後，疾病惡化 ...

#70. Atezolizumab Biosimilar - Research Grade [ICH4018] - ichorbio

Atezolizumab is a fully-humanized IgG1 monoclonal antibody directed against PD-L1 (programmed cell death 1 ligand 1). Atezolizumab has been ...

#71. Atezolizumab Overview - Creative Biolabs

NCT03276468 Recruiting September 8, 2017 NCT03125928 Recruiting April 24, 2017 NCT03353831 Not yet recruiting November 27, 2017 NCT03120676 Recruiting April 19, 2017

#72. Buy Tecentriq (Atezolizumab) Online • Price & Costs

Tecentriq (atezolizumab) is a medication used for the treatment of locally advanced or metastatic urothelial carcinoma, for the treatment of metastatic ...

#73. Murine Anti-PD-L1 mAb - InvivoGen

Notably, atezolizumab contains an engineered constant region designed to limit effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and ...

#74. Roche's Tecentriq prolongs OS in SCLC - European ...

Now, Roche's US arm Genentech announced that the company's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) improved survival by ...

#75. Atezolizumab

Atezolizumab was approved by the U.S. Food and Drug Administration (FDA) on May 18, 2016. · Atezolizumab is a programmed cell death-Ligand （PD- ...

#76. 肺鱗癌又添新療法，Atezolizumab四藥聯合中位總生存期近20 ...

12月6日，美國食品和藥物管理局（FDA）批准了免疫治療藥物atezolizumab（Tecentriq）聯合貝伐單抗（Avastin）， 紫杉醇（紫杉醇）和卡鉑的標準方案， ...

#77. Roche 1 Tecentriq (Atezolizumab), Packaging Type: Vial , for ...

United Speciality Pharma - Offering Roche 1 Tecentriq (Atezolizumab), Packaging Type: Vial , for Personal at Rs 210000/box in Mumbai, Maharashtra.

#78. Atezolizumab - farmaci contro il cancro | alcase.eu

Atezolizumab agisce come immunomodulatore, bloccando il ligando della proteina della morte cellulare, nello specifico l'interazione fra PD-L1 e PD-1.

#79. Seven and Eight Biopharma's BDB001 in ... - Yahoo Finance

The results show that BDB001 in combination with atezolizumab is well tolerated with evidence of robust immune activation leading to ...

#80. Atezolizumab 肺線癌第三期臨床實驗表現亮眼 - 探索癌症

Atezolizumab NSCLC第三期臨床實驗收ALK EGFR標靶化療失效的病人全球共1225名病人細節將在近期公布http://www.roche.com/media/store/re.

#81. Elsevier's 2022 Intravenous Medications - E-Book: A Handbook ...

Atezolizumab can cause other severe and fatal immune-mediated adverse reactions that ... May occur during or after treatment with atezolizumab; see Monitor.

#82. Atezolizumab - Anwendung, Wirkung, Nebenwirkungen

Atezolizumab ist ein modifizierter, humanisierter monoklonaler Immunglobulin G1 (IgG1)-Antikörper, der direkt an den programmierten Zelltod- ...

#83. Tecentriq (Atezolizumab) distributor, wholesaler - Rasso ...

Tecentriq (Atezolizumab) is a fully humanized, engineered monoclonal antibody of IgG1isotype against the protein programmed cell death-ligand 1 (PD-L1).

#84. Seven and Eight Biopharma's BDB001 in ... - Business Wire

“It is encouraging to see that BDB001 in combination with atezolizumab can be safely delivered intravenously and produces clinical responses ...

#85. La EMA da el vistos bueno al atezolizumab para tratar en ...

El estudio fase III IMpower110 mostró que la monoterapia con atezolizumab mejoró la supervivencia global en 7,1 meses en comparación con ...

#86. Atezolizumab Market Size, Growth (2021-2028) - Energy Siren

Atezolizumab Market Size, Growth (2021-2028) | Top Companies – Genentech (Roche),. New Jersey, United States,- The recent report on “ ...

#87. The Basics of Cancer Immunotherapy - 第 67 頁 - Google 圖書結果

Patients in the TC2/3 or IC2/3 subgroups treated with atezolizumab had an improved overall survival (15.1 months, 95% CI 8.4–non-estimable) compared with ...

#88. Atezolizumab ya está disponible para tumores de pulmón y ...

Se trata de la primera inmunoterapia para este tumor urológico y el primer antiPD-L1 para el carcinoma pulmonar. Atezolizumab se ha diseñado ...

#89. Empresas.- PharmaMar presentará datos sobre lurbinectedin ...

Empresas.- PharmaMar presentará datos sobre lurbinectedin y atezolizumab en el congreso de la SITC.

#90. Atezolizumab en el cáncer vesical - info-farmacia

Atezolizumab (Tecentriq®) fue inicialmente autorizado para el carcinoma urotelial, en estadios avanzados, tanto localizados como metastásicos, y ...

#91. Translational Pancreatic Cancer Research: From Understanding ...

Trial ID NCT03193190 Table 14.1 (continued) CombinationCombination-arm 1 Patient eligibility arm 2 Status criteria Atezolizumab (αPD-L1), chemotherapy, ...

#92. 1.6.01 Atezolizumab - 醫健事

藥名：, Atezolizumab. 商品名：, Tecentriq ®. 中文名: 癌自禦. 功效: 全球首款獲准使用的PD-L1免疫治療. 上市年份: 2018年在香港註冊. 性質：, 注射劑 ...

#93. Dostępność immunoterapii dla polskich pacjentów - 2021 rok

Atezolizumab od 2019 roku otrzymują pacjenci spełniający kryteria ... mogą liczyć na nowe leczenie z wykorzystaniem cząsteczki atezolizumab.

#94. Immunotherapy and The Regulatory Immune System in Blood ...

PD-L1 inhibitor Trial name Status Phase Intervention/treatment Immunological target Atezolizumab NCT02926833 Recruiting I/II Atezolizumab, ...

#95. Davis's Canadian Drug Guide for Nurses - 第 194 頁 - Google 圖書結果

SCLC IV (Adults): 1200 mg every 3 wk (followed by carboplatin and etoposide) for 4 cycles, then continue with atezolizumab (as monotherapy) at a dose of 840 ...

#96. FDA Approves Atezolizumab With Chemotherapy and ...

Atezolizumab, carboplatin and paclitaxel (3-drug regimen); or; Carboplatin, paclitaxel, and bevacizumab (control arm). Following completion of 4 ...

#97. Pathologists Discuss Actionable Mutations and Testing in ...

IMpassion130 randomized patients to atezolizumab (a checkpoint inhibitor) ... test for atezolizumab and PD-L1 assessment in tumor cells, ...